Neuralstem Announces Proposed Public Offering ROCKVILLE,

New Post Public Reply Private Reply Replies (1) Message Board

Sep 14, 2012 at 6:43 AM

Neuralstem Announces Proposed Public Offering

ROCKVILLE, Md. , Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. Neuralstem intends to use the net proceeds from the offering for general corporate purposes, including research and development expenditures, working capital, capital expenditures, clinical trial expenditures and other general corporate purposes.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective. A prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY , 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com . Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov .

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012 .

SOURCE Neuralstem, Inc.

Deanne Eagle - Media Relations, +1-917-837-5866; Susan Roush - Investor Relations, +1-818-222-8330

Palisade Bio, Inc. (PALI) Stock Research Links

PALI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epsilor Launches Cutting-Edge 6T Battery for Military Use

A Big Leap for Military Power on the Go Seems like Epsilor just raised the stakes in the military tech race with their latest 6T battery, a piece of kit boasting some serious muscle at 4,400Wh with 174Ah thrown in for good measure. Serving up a military-grade solution where endurance and performance are necessities, they've entered production just in time for the...

Veteran Suicide Prevention: The Urgency Behind CVN's Push

Veteran suicide is a crisis staring us square in the face, with rates 60% higher than the general population. It's a grim reminder that the mental toll on those who've served is a deep chasm hard to bridge. Cohen Veterans Network (CVN) is stepping up to the plate with a new campaign dubbed 'Ask Anyway: Conversations to Save a Life'. This isn't just any awareness...

Hyperscale Recalibrates: AI Boom or Risky Bet?

Is Hyperscale Making the Right Move? Hyperscale Data, Inc. waved goodbye to the Bitcoin mining days to clear the stage for artificial intelligence (AI). But is this strategic leap off the blockchain and into AI territory as golden as promised? Whisper around the street is it could turn into a $3 billion windfall. But let's chew through the details before toasting...

UNISORB Expands Reach with BILZ Acquisition

UNISORB Acquisition: A Game-Changer for Industrial Solutions This ain't the first time a company took over another to expand its footprint, but UNISORB's latest move to scoop up BILZ-USA is worth a closer look. Everybody's talking about this takeover that throws UNISORB right into the spotlight of North America's industrial sector. Naming them the exclusive distributor of...

AEC Firms Revamp Strategies Amid Talent Tug-of-War

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Lindian's Bold Leap into Rare Earths Processing

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Empirik.ai's $21M for AI in Infrastructure Revolution

AI-Powered Infrastructure Takes the Stage Well, here's a tech gambit going full steam: empirik.ai just hit the digital scene with a $21 million war chest. Fresh out of the stealth shadows, they've got big names like Sequoia Capital, S32, Canapi Ventures, and Alumni Ventures stamping their ticket. What's the fuss? They're rolling out the first AI agent designed to...

ZPMC Names Two New 38,000 DWT Vessels for Chipolbrok

Navigating Uncharted Waters with New Vessels Some days, you see a giant leap in an industry and think, "Well, someone's got ambition." Here, we're talking about ZPMC's gutsy naming ceremony for two spanking new 38,000 DWT multipurpose heavy-lift ships destined for Chipolbrok, happening fresh off the docks in Shanghai. Specifications That Make Waves Imagine a vessel the...

BlueSky Enters Nashville: In-Home Vet Care Begins

Nashville Welcomes A New Wave of Pet Care In a world where convenience is king, BlueSky At-Home Veterinary Care is stepping up to the plate—or should I say, doorstep—by rolling out its fresh take on veterinary services in Nashville. Kicking off on September 15, 2026, this isn't just any ol' run-of-the-mill clinic opening. We're talking about vets coming straight to...

CGX Hits Big Stage with New Obstacle Racing Shoes

A Bold Step into Obstacle Racing Today, CGX is shaking things up in the world of obstacle racing. The Chinese footwear brand launched its CGX&OCR R1010 and R1020 shoes right at the UIPM 2026 Obstacle World Championships in Beijing. Talk about a grand entrance. Targeting high-stakes international competition, these shoes are set to redefine how athletes tackle those...